Related Experiment Video
Updated: Jun 8, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Stereotactic body radiation therapy for oligometastases
Simon S Lo1, Bin S Teh, Nina A Mayr
1Department of Radiation Oncology, Arthur G. James Cancer Hospital, Ohio State University, Columbus, Ohio 43210, USA. Simon.Lo@osumc.edu
Discovery Medicine
|September 30, 2010
Summary
Stereotactic body radiation therapy shows promise for treating oligometastases, potentially improving survival. Further research with longer follow-up is needed to confirm its role and explore combination therapies for better patient outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Emerging evidence suggests an oligometastatic state where limited metastatic sites may benefit from aggressive local treatment.
- Stereotactic body radiation therapy (SBRT) is a leading local therapy option for oligometastases, particularly in the lung and liver.
- Current research indicates promising outcomes with SBRT for oligometastatic disease.
Purpose of the Study:
- To evaluate the efficacy and role of stereotactic body radiation therapy in managing patients with oligometastases.
- To highlight the need for extended follow-up periods in existing studies.
- To identify future research directions, including the combination of SBRT with systemic therapies.
Main Methods:
- Review of retrospective studies and clinical trials investigating SBRT for oligometastases.
- Analysis of treatment outcomes and survival data.
- Identification of limitations in current research, such as short follow-up intervals.
Main Results:
- Retrospective data and clinical trials show encouraging results for SBRT in treating oligometastases.
- SBRT is a feasible and effective local treatment modality for oligometastatic disease in various sites.
- A significant limitation is the short follow-up duration in most published studies.
Conclusions:
- SBRT demonstrates potential as a beneficial treatment for oligometastases, possibly improving survival.
- Longer follow-up studies are crucial to establish the definitive role of SBRT in oligometastatic cancer management.
- Future strategies should investigate combining SBRT with novel systemic therapies to address the high risk of distant progression.
